BARCELONA, Spain--(BUSINESS WIRE)--Ferrer, a B Corp-certified international pharmaceutical company, has announced the dosing of the first participant in the Phase II clinical trial, PROSPER. The study ...

The recent discovery of a unique protein pattern in spinal fluid may make earlier diagnosis of progressive supranuclear palsy a reality. Researchers at the University of California San Francisco (CA, ...

A clinical trial that will test three drugs concurrently, and could include more, represents new hope for patients with progressive supranuclear palsy (PSP), an incurable neurodegenerative disorder ...

Ferrer Advances Research into Progressive Supranuclear Palsy (PSP) with the Inclusion of the First Participant in a Phase II Clinical Trial Ferrer, a B Corp-certified international pharmaceutical ...

This is a randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy, safety, and pharmacokinetics of FNP-223 (oral formulation) in slowing the progression ...

LILLE, France--(BUSINESS WIRE)--Alzprotect, a French biopharmaceutical company, is pleased to announce the successful completion of the open-label extension (OLE) phase following the Phase 2a clinical ...

Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are sporadic four-repeat tauopathies that have characteristic clinical and neuropathologic profiles, but also share overlapping ...

CHICAGO -- Civil rights activist Rev. Jesse Jackson was hospitalized on Wednesday in Chicago, according to the Rainbow PUSH Coalition. Sources told our sister station WLS that Jackson was being ...